Economics of cancer biomarkers

Personalized Medicine

Volumn 9, Issue 8, 2012, Pages 829-837

  Schneider, John E ^a   Sidhu, Manpreet K ^a   Doucet, Cynthia ^b   Kiss, Noemi ^a   Ohsfeldt, Robert L ^a,c   Chalfin, Donald ^b  

^a ICON PLC   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

biomarkers; cancer; economics

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; IRINOTECAN; TRASTUZUMAB; TUMOR MARKER;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER THERAPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LEUKEMIA; OVARY CANCER; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER;

EID: 84869819316     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.87     Document Type: Review

References (33)

1. US Congress. Technological Change and the Growth of Health Care Spending. Congressional Budget Office, DC, USA (2008).
2. Yao L. Institute offers blueprint for U.S. Effort to compare medical treatments. Wall Street Journal, 1 July 2009.).
3. Wilson CL, Schultz S, Waldman SA. Cancer biomarkers where medicine, business and public policy intersect. Biotechnol. Healthcare February, 33-42 (2007).
4. Jaffe CC. Pathology and Imaging In Biomarker Development. NCI, MD, USA (2001).
5. Drummond M, McGuire A. Economic Evaluation in Health Care: MERGING Theory with Practice. Oxford University Press, NY, USA (2001).
6. Gold MR, Russell LB, Siegel JE, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
7. Chalfin DB, Cohen IL, Lambrinos J. The economics and cost-effectiveness of critical care medicine. Intensive Care Med. 21(11), 952-961 (1995).
8. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K. Searching for cost effectiveness thresholds in the NHS. Health Policy 91(3), 239-245 (2009).
9. Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. Nass SJ, Moses HL (Eds). The National Academies Press, DC, USA (2007).
10. Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers' coverage of personalized medicine. J. Oncol. Pract. 7(Suppl. 3), S18-S24 (2011).
11. Chalkidou K, Lord J, Fischer A, Littlejohns P. Evidence-based decision making: When should we wait for more information? Health Aff. (Millwood) 27(6), 1642-1653 (2008).
12. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff. (Millwood) 29(11), 1988-1994 (2010).
13. Deverka PA, McLeod HL. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin. Pharmacol. Ther. 84(2), 191-193 (2008).
14. Etzioni R, Urban N, Ramsey S et al. The case for early detection. Nat. Rev. Cancer 3(4), 1-10 (2003).
15. Cohen J, Neuman P, Weinstein M. Does preventive care save money? health economics and the presidential candidates. N. Engl. J. Med. 358(7), 661-663 (2008). (Pubitemid 351240744)
16. Dennis LK, Lynch CF, Smith EM. Cancer. In: PUBLIC Health and Preventive Medicine (15th Edition). Wallace RB (Ed.). McGraw- Hill Medical, NY, USA (2008).
17. Kumar S, Mohan A, Guleria R. Biomarkers in cancer screening, research and detection: Present and future: A review. Biomarkers 11, 385-405 (2006). (Pubitemid 44364079)
18. Macdonald CF. Assessing secondary prevention methods for cervical cancer: Costs and benefits in managed care. Am. J. Manag. Care 14(6 Suppl. 1), S185-S192 (2008).
19. Tengs TO, Adams ME, Pliskin JS et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal. 15(3), 369-391 (1995).
20. Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol. Oncol. 111(2), 179-187 (2008).
21. Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol. Ther. 22(2), 135-146 (2005). (Pubitemid 41039702)
22. Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. doi:10.1038/tpj.2011.63 (2012) (Epub ahead of print).
23. Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: An update. Cancer Immunol. Immunother. 57(6), 759-775 (2008).
24. Helleman J, van der Vlies D, Jansen MP et al. Serum proteomic patterns for ovarian cancer monitoring. Int. J. Gynecol. Cancer 18(5), 985-995 (2008).
25. Allison M. Is personalized medicine finally arriving? Nat. Biotechnol. 26(5), 509-517 (2008). (Pubitemid 351668034)
26. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol. Ther. 6(3), 308-312 (2007). (Pubitemid 47328293)
27. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6(4), 287-293 (2007). (Pubitemid 46505879)
28. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: A critical and systematic review. Pharmacoeconomics 28(11), 1001-1013 (2010).
29. Koopman M, Venderbosch S, van Tinteren H et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the Phase III randomised CAIRO study. Eur. J. Cancer 45(11), 1999-2006 (2009).
30. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001). (Pubitemid 32222155)
31. Marchionni L, Wilson RF, Marinopoulos SS et al. Impact of gene expression profiling tests on breast cancer outcomes. Evid. Rep. Technol. Assess. (Full Rep.) 160, 1-105 (2007).
32. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am. J. Manag. Care 11(5), 313-324 (2005). (Pubitemid 40646936)
33. Abrahams E, Silver M. The case for personalized medicine. J. Diabetes Sci. Technol. 3(4), 680-684 (2009